Literature DB >> 12969901

Treatment of multiple myeloma.

Seema Singhal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12969901      PMCID： PMC194073          DOI： 10.1136/bmj.327.7415.575

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Authors:  Philippe Moreau; Thierry Facon; Michel Attal; Cyrille Hulin; Mauricette Michallet; Frédéric Maloisel; Jean-Jacques Sotto; François Guilhot; Gérald Marit; Chantal Doyen; Jérôme Jaubert; Jean-Gabriel Fuzibet; Sylvie François; Lotfi Benboubker; Matthieu Monconduit; Laurent Voillat; Margaret Macro; Christian Berthou; Véronique Dorvaux; Bernard Pignon; Bernard Rio; Thomas Matthes; Philippe Casassus; Denis Caillot; Norbert Najman; Bernard Grosbois; Régis Bataille; Jean-Luc Harousseau
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Authors:  B Barlogie; S Jagannath; K R Desikan; S Mattox; D Vesole; D Siegel; G Tricot; N Munshi; A Fassas; S Singhal; J Mehta; E Anaissie; D Dhodapkar; S Naucke; J Cromer; J Sawyer; J Epstein; D Spoon; D Ayers; B Cheson; J Crowley
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

3.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

Authors:  J P Fermand; P Ravaud; S Chevret; M Divine; V Leblond; C Belanger; M Macro; E Pertuiset; F Dreyfus; X Mariette; C Boccacio; J C Brouet
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

4.  Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.

Authors:  S Singhal; R Powles; B Sirohi; J Treleaven; S Kulkarni; J Mehta
Journal:  Bone Marrow Transplant       Date:  2002-11       Impact factor: 5.483

5.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

6.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Authors:  J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245

Review 7.  Graft-versus-myeloma.

Authors:  J Mehta; S Singhal
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

8.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

9.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

Review 10.  Novel therapies in multiple myeloma.

Authors:  Seema Singhal; Jayesh Mehta
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.319
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.